Inner Mongolia Furui Medical Science Co., Ltd. (SHE:300049)
China · Delayed Price · Currency is CNY 66.42
+0.23 (0.35%)
Feb 13, 2026, 3:04 PM CST
SHE:300049 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,463 | 1,342 | 1,147 | 1,001 | 891.56 | 800.96 |
Other Revenue | 7.49 | 7.49 | 6.9 | 7.37 | 6.93 | 6.57 |
| 1,470 | 1,349 | 1,154 | 1,009 | 898.48 | 807.53 | |
Revenue Growth (YoY) | 10.82% | 16.93% | 14.37% | 12.27% | 11.26% | -2.91% |
Cost of Revenue | 392.88 | 350.73 | 291.39 | 267.67 | 239.14 | 226.65 |
Gross Profit | 1,077 | 998.28 | 862.34 | 741.09 | 659.34 | 580.88 |
Selling, General & Admin | 601.96 | 584.24 | 527.56 | 474.49 | 405.7 | 361.47 |
Research & Development | 107.84 | 99.49 | 82.47 | 70.82 | 64.79 | 65.82 |
Other Operating Expenses | 8.86 | 8.08 | 10.43 | 10.79 | 12.5 | 11.39 |
Operating Expenses | 741.29 | 711.59 | 622 | 562.68 | 491.94 | 440.51 |
Operating Income | 336.02 | 286.69 | 240.34 | 178.41 | 167.4 | 140.38 |
Interest Expense | -3.16 | -2.77 | -0.9 | -1.58 | -2.33 | -3.21 |
Interest & Investment Income | 12.77 | 16.07 | 12.38 | 9.73 | 10.54 | 3.41 |
Currency Exchange Gain (Loss) | 10.37 | 10.37 | -2.31 | 7.93 | 16.48 | -12.48 |
Other Non Operating Income (Expenses) | -31.27 | -2.03 | 4.08 | -1.28 | -0.26 | -0.25 |
EBT Excluding Unusual Items | 324.74 | 308.34 | 253.59 | 193.21 | 191.83 | 127.84 |
Impairment of Goodwill | -7.7 | -7.7 | - | - | - | - |
Gain (Loss) on Sale of Investments | -26.88 | -23.11 | - | - | - | -1.6 |
Gain (Loss) on Sale of Assets | 0.31 | -0.31 | -0.82 | -1.86 | -3.46 | -6.93 |
Asset Writedown | -0.33 | -0 | -4.71 | -0 | - | - |
Other Unusual Items | -6.66 | -6.66 | -12.66 | 0.29 | 0.77 | -5.32 |
Pretax Income | 283.48 | 270.55 | 235.4 | 191.63 | 189.14 | 113.99 |
Income Tax Expense | 84.76 | 74.67 | 58.29 | 46.22 | 41.1 | 23.72 |
Earnings From Continuing Operations | 198.72 | 195.88 | 177.11 | 145.41 | 148.04 | 90.27 |
Minority Interest in Earnings | -75.55 | -82.59 | -75.55 | -47.52 | -52.57 | -28.36 |
Net Income | 123.17 | 113.29 | 101.56 | 97.89 | 95.47 | 61.91 |
Net Income to Common | 123.17 | 113.29 | 101.56 | 97.89 | 95.47 | 61.91 |
Net Income Growth | -5.55% | 11.54% | 3.75% | 2.54% | 54.22% | 42.69% |
Shares Outstanding (Basic) | 262 | 264 | 263 | 263 | 260 | 256 |
Shares Outstanding (Diluted) | 262 | 264 | 263 | 263 | 260 | 256 |
Shares Change (YoY) | -1.18% | 0.50% | -0.01% | 1.30% | 1.31% | 0.03% |
EPS (Basic) | 0.47 | 0.43 | 0.39 | 0.37 | 0.37 | 0.24 |
EPS (Diluted) | 0.47 | 0.43 | 0.39 | 0.37 | 0.37 | 0.24 |
EPS Growth | -4.42% | 10.98% | 3.76% | 1.22% | 52.22% | 42.65% |
Free Cash Flow | 99.3 | 2.44 | 115.66 | 98.69 | 142.94 | 90.41 |
Free Cash Flow Per Share | 0.38 | 0.01 | 0.44 | 0.38 | 0.55 | 0.35 |
Dividend Per Share | - | - | - | 0.200 | - | - |
Gross Margin | 73.28% | 74.00% | 74.74% | 73.47% | 73.38% | 71.93% |
Operating Margin | 22.86% | 21.25% | 20.83% | 17.69% | 18.63% | 17.38% |
Profit Margin | 8.38% | 8.40% | 8.80% | 9.70% | 10.63% | 7.67% |
Free Cash Flow Margin | 6.75% | 0.18% | 10.03% | 9.78% | 15.91% | 11.20% |
EBITDA | 411.97 | 358.88 | 307.52 | 236.39 | 221.12 | 209.72 |
EBITDA Margin | 28.02% | 26.60% | 26.65% | 23.43% | 24.61% | 25.97% |
D&A For EBITDA | 75.95 | 72.19 | 67.18 | 57.98 | 53.71 | 69.35 |
EBIT | 336.02 | 286.69 | 240.34 | 178.41 | 167.4 | 140.38 |
EBIT Margin | 22.86% | 21.25% | 20.83% | 17.69% | 18.63% | 17.38% |
Effective Tax Rate | 29.90% | 27.60% | 24.76% | 24.12% | 21.73% | 20.81% |
Revenue as Reported | 1,470 | 1,349 | 1,154 | 1,009 | 898.48 | 807.53 |
Advertising Expenses | - | 3.34 | 4.76 | 9.83 | 9.3 | 5.62 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.